Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced RCC.
figure
posted on 2022-06-27, 07:34 authored by Jianxin Pang, Peihao Wu, Yanqing Jiang, Junyan Wu, Kaifeng Qiu, Ruizhe Liu<p> <strong>Figure S1.</strong> Kaplan–Meier curves and modelled curves. </p>
